Abstract
Background
The divalent cation Calcium (Ca2+) regulates a wide range of processes in disparate cell types. Within insulin-producing β-cells, increases in cytosolic Ca2+ directly stimulate insulin vesicle exocytosis, but also initiate multiple signaling pathways. Mediated through activation of downstream kinases and transcription factors, Ca2+-regulated signaling pathways leverage substantial influence on a number of critical cellular processes within the β-cell. Additionally, there is evidence that prolonged activation of these same pathways is detrimental to β-cell health and may contribute to Type 2 Diabetes pathogenesis.
Scope of review
This review aims to briefly highlight canonical Ca2+ signaling pathways in β-cells and how β-cells regulate the movement of Ca2+ across numerous organelles and microdomains. As a main focus, this review synthesizes experimental data from in vitro and in vivo models on both the beneficial and detrimental effects of Ca2+ signaling pathways for β-cell function and health.
Major conclusions
Acute increases in intracellular Ca2+ stimulate a number of signaling cascades, resulting in (de-)phosphorylation events and activation of downstream transcription factors. The short-term stimulation of these Ca2+ signaling pathways promotes numerous cellular processes critical to β-cell function, including increased viability, replication, and insulin production and secretion. Conversely, chronic stimulation of Ca2+ signaling pathways increases β-cell ER stress and results in the loss of β-cell differentiation status. Together, decades of study demonstrate that Ca2+ movement is tightly regulated within the β-cell, which is at least partially due to its dual roles as a potent signaling molecule.
Keywords: β-cells, Diabetes, Ca2+, CREB, NFAT, Calmodulin, Calcineurin, CaMK
Graphical abstract

1. Introduction
Elevated cytosolic Ca2+ (Ca2+i) initiates a broad range of physiological responses in excitatory cells, from promoting exocytosis in endocrine cells and neurons to muscle contraction in myocytes. These processes are triggered within microseconds of Ca2+ influx into the cytosol [1]. Elevations in Ca2+i that persist for seconds to minutes produce long-term responses, dependent on the activation of downstream signaling pathways [1]. Dysregulation of the Ca2+ signaling cascade contributes to the dysfunction of multiple tissues and cell types in metabolic disorders [2], [3], [4].
Within insulin-producing β-cells, increased Ca2+i causes insulin granule exocytosis, but Ca2+-mediated signaling pathways also have critical roles in promoting the function, survival, and proliferation of these cells. This review aims to highlight sources of Ca2+i, important mediators of β-cell Ca2+ signaling and their relevance to β-cell biology and type 2 diabetes (T2D).
2. Ca2+ handling in β-cells
β-cells regulate the systemic response to hyperglycemia through the production and secretion of the hormone insulin. Given the detrimental effects of either impaired or elevated insulin release, the increase in Ca2+i that effectively stimulates insulin exocytosis from the β-cell must be closely regulated. This tight control requires the cooperation between multiple Ca2+ exchangers, pumps, and channels [5].
In the postprandial state, glucose elicits the influx of Ca2+ through L-type voltage-gated Ca2+ channels (L-VGCCs). Mediated via glucose metabolism and ATP production, shifts in the ratio of ATP to ADP (ATP:ADP) within the β-cell result in the closure of ATP-sensitive potassium (KATP) channels and membrane depolarization. In human β-cells, L-VGCCs are activated at a membrane potential of −40 mV and, in concert with T-type and P/Q-type Ca2+ channels, allow Ca2+ influx to elicit insulin exocytosis [6]. Ca2+ flux across the β-cell plasma membrane is further regulated by a number of metabolites and nutrients including free fatty acid signaling and cAMP [7], likely through the activation of PKA and subsequent phosphorylation of voltage gated Ca2+ channels [8]. Furthermore, hormones including leptin [9] and ghrelin [10] and classical neurotransmitters [11], [12] also regulate Ca2+ influx.
In addition to influx of extracellular Ca2+, there are multiple membrane-bound organelles that regulate Ca2+i levels, including the nucleus, endoplasmic reticulum (ER), mitochondria, Golgi, as well as vesicles and granules [13], [14]. Intracellular Ca2+ stores are distinguished based on their sensitivity to inositol-1,4,5-trisphosphate (IP3), nicotinic acid adenine dinucleotide phosphate (NAADP), or ryanodine (summarized in Figure 1). Additionally, intracellular Ca2+ stores are responsive to circulating signals, including insulin [15], [16], circulating fatty acids [17], IL-6 [18], and incretin hormones [19], [20], [21], [22], [23].
Figure 1.
Schematic of β-cell Ca2+homeostasis pathways. Extracellular Ca2+ influx in β-cells is triggered by the uptake of glucose through glucose transporters (GLUT2 in rodents; GLUT1 in humans) and subsequent metabolism. This shifts the ratio of ATP to ADP, which closes the ATP-sensitive potassium channel (KATP) and opens L-type voltage-gated Ca2+ channels (L-VGCCs) (A). There are also intracellular Ca2+ pools which contribute to the increase in cytosolic Ca2+ (Ca2+i), including through the ryanodine receptor (RyR) on the ER membrane, through a process termed “Ca2+-induced Ca2+ release” (B). Additionally, Ca2+ is released following glucose metabolism and production of NAADP by CD38, which acts through two pore channel 1 (TPC1) found on acidic vesicles including insulin granules (C). Finally, intracellular Ca2+ can be released through the activation of IP3 receptors (IP3R) found on the ER membrane and on insulin granules. IP3Rs are stimulated by the production of IP3 from PIP2 following activation of phospholipase C (PLC) by increased Ca2+i or by Gαq-coupled G-protein receptors including the free fatty acid receptor 1 (FFAR1/GPR40) and acetylcholine receptor (AchR) (D). Following the rise in Ca2+i levels, the plasma membrane Ca2+ ATPase (PMCA) pumps Ca2+ out of the cell (E). Ca2+ is also sequestered in the mitochondria by voltage-dependent anion channels and the mitochondrial Ca2+ uniporter (F) and the ER through the actions of the sarcoplasmic endoplasmic reticulum Ca2+ ATPase (SERCA) (G). Ca2+ concentrations within different cellular compartments are shown (black: basal; green: stimulated).
Ca2+ release from IP3-sensitive pools occurs through activation of the IP3 receptor (IP3R), which is expressed on the ER membrane [24], insulin granules, and Golgi [25], [26]. IP3 is generated downstream of certain Gαq-associated G protein coupled receptors, such as the free fatty acid receptor GPR40 (FFAR1), which signals through phospholipase C (PLC) [27]. PLC then converts phosphatidylinositol-4,5-bisphosphateinositol (PIP2) to IP3. Alternatively, PLC is also activated by an increase in Ca2+i; suggesting other sources of Ca2+ (i.e. extracellular, NAADH-responsive) can trigger release of Ca2+ from IP3R-responsive stores [28], [29].
A second source of Ca2+i is the NAADP-responsive pool. Within β-cells, NAADP acts as a second messenger of glucose metabolism, as elevated glucose exposure rapidly increases β-cell NAADP content [30]. NAADP is generated from NADP through ADP-ribosyl cyclases (ARC) such as CD38 [31] and mediates Ca2+ release from acidic vesicles such as lysosomes and insulin granules [32] through two pore channel 1 [15], [33], [34]. The NAADP-sensitive stores are required for glucose-stimulated elevations in Ca2+i, as their inhibition is sufficient to impair glucose-stimulated insulin secretion [35], [36].
The third source for Ca2+i is the ryanodine-sensitive pool [37]. The ryanodine receptors (RyRs) are homotetramers with a combined molecular mass of ∼2.3 MDa [38]. While controversy has persisted as to which RyR family members are expressed in β-cells [32], [39], this may be due to the naturally low expression of RyRs, differences in cell type (immortalized cell line or primary tissue) or detection method (less sensitive western blot or PCR), as well as possible differences in splicing. More recently, examination of multiple exons within all three RyR family members in human islets demonstrated detectable expression of all family members [40]. RyRs have been proposed to exist on the β-cell ER [41], insulin granules [32], early endosomes [37] and the plasma membrane [42]. Functionally, RyR channels can be activated by ATP, cAMP and long chain acyl CoA [43], as well as the second messenger cyclic ADP ribose (cADPR), which is produced from NAD+ by ARC enzymes, including CD38 [44]. Activation of RyRs promotes glucose-independent insulin release [37]. Additionally, RyRs contribute to glucose-stimulated insulin secretion by mediating the process of Ca2+-induced Ca2+ release (CICR) [32] through several possible mechanisms, depending on which Ca2+ store expresses RyRs. With ER-localized RyRs, CICR is thought to increase Ca2+i in close proximity to mitochondria and maintain high rates of ATP generation. Similarly, RyRs expressed on the insulin granule increase Ca2+i in the immediate proximity of the insulin granule and facilitate Ca2+-dependent vesicle docking and fusion [43].
Beside the regulation of these Ca2+-sensitive stores, mitochondria are additional β-cell organelles in which Ca2+ handling is tightly regulated and critical for function [45]. Ca2+ is exported from mitochondria via the Na+/Ca2+ exchanger (NCLX) [46], while Ca2+ influx into the mitochondrial matrix is achieved through voltage-dependent anion channels (VDACs) in the outer mitochondrial membrane, and the mitochondrial Ca2+ uniporter (MCU) complex in the inner mitochondrial membrane [47], [48]. Regulation of MCU by mitochondrial Ca2+ uptake 1 (MICU1) is critical for mitochondrial function and β-cell function, as knockdown of MICU1 in INS1 cells reduces Ca2+ influx into mitochondria, resulting in reduced glucose-stimulated mitochondrial respiration, ATP production, and insulin secretion [49], [50]. Notably, mitochondrial Ca2+ entry from the cytosol is limited by the low affinity of the MCU, but microdomains between the ER and mitochondria (mitochondria-associated membranes; MAMs), tethered through GRP75 and mitofusin 1 and 2, facilitate the rapid transport of large quantities of Ca2+ from the ER into mitochondria following IP3R- or RyR2-mediated ER Ca2+ release [47], [48], [51]. Functionally, Ca2+ influx into the mitochondria during periods of high metabolic demands ensures adequate ATP production to maintain insulin secretion by increasing the availability of metabolic substrates and stimulating the TCA cycle (possibly through activation of 2-oxoglutarate dehydrogenase and isocitrate dehydrogenase) [45]. Together, these studies demonstrate the importance of tightly regulated mitochondrial Ca2+ levels.
β-cells maintain tight control of Ca2+i levels through the regulation of extracellular Ca2+ influx and the movement of Ca2+ within intracellular depots. The degree of this complexity is illustrated through Ca2+ microdomains. Basal levels of free intracellular Ca2+ are approximately 100 nM, 20,000× lower than free extracellular Ca2+. Following stimulation, whole cell Ca2+i increases to 300–1000 nM, but more responsive Ca2+ microdomains exist within multiple subcellular locales including dense core vesicles, ER, mitochondria, subplasmalemma, and within the nucleus [52].
Each of these microdomains have functional consequences. The increase in nuclear Ca2+ is required for activation of cAMP response element binding (CREB) [53], [54]. Ca2+ microdomains surrounding dense core vesicles have been postulated to amplify insulin secretion by increasing Ca2+ concentrations in close proximity to Ca2+-dependent synaptic proteins [55], and the Ca2+ microdomains formed within the mitochondria following high glucose exposure are required for mitochondrial function and second phase insulin secretion [56].
The regulation of Ca2+ handling is highly complex, requiring multiple receptors and channels on multiple organelles and the plasma membrane. The potency of Ca2+ as a signaling molecule is a major reason for this degree of intricacy.
3. Ca2+ signaling pathways
Once elevated, Ca2+i initiates multiple signaling cascades by binding to and activating the Ca2+ sensor protein Calmodulin (CaM). CaM then undergoes a conformational change, allowing it to activate numerous downstream targets [57]. Interaction between CaM and its partners is highly diverse; certain proteins are nearly continuously bound to CaM, while others interact with CaM specifically under either low or high Ca2+i conditions [58]. CaM-mediated activation can occur through facilitated dimerization, remodeling of active sites, or removal of autoinhibition [59].
The Ca2+/Calmodulin-dependent protein kinases (CaMK) are one class of proteins activated by Ca2+-bound CaM. Of the CaMK isoforms [60], CaMKK1 [61], CaMKK2 [62], traces of CaMKI isoforms (α, γ, δ) [63], [64], [65], all CaMKII isoforms (α, β, γ, δ) [66], and CaMKIV [61] have been detected in β-cells. Targets of the CaMKs include the transcription factor CREB. Under low Ca2+ conditions, inactive CREB is bound to consensus sites (TGACGTCA) [67], whereas increases in Ca2+i result in CREB activation through a CaMK-dependent pathway [68], [69]. Phosphorylated CREB then interacts with its co-factors CREB regulated transcription coactivator 2 (CRTC2) and CREB binding protein (CBP) to promote target gene transcription [70]. Besides Ca2+i-mediated phosphorylation of CREB, Ca2+ signaling pathways also increase CREB activity via CRTC2. Activation of the phosphatase Calcineurin (CaN) results in the dephosphorylation of cytoplasmic CRTC2, which subsequently dissociates from cytoplasmic 14-3-3 chaperone proteins and translocates to the nucleus, where it increases CREB transcriptional activity [71]. CRTC2 is exported from the nucleus following re-phosphorylation by microtubule affinity regulating kinase 2 (MARK2) [72] and salt inducible kinase 2 (SIK2) [71].
Independent of the CaMK/CREB pathway, CaM also activates a separate signaling cascade through CaN. CaN has many target proteins, including nuclear factor of activated T cells (NFAT) [73] and myocyte enhancer factor-2 (MEF2) [74] family members. CaN-mediated dephosphorylation results in NFAT nuclear translocation and transcriptional activation [73]. NFAT proteins are exported from the nucleus via re-phosphorylation by the kinases DYRK1A and GSK3β [75].
In addition to CaMK and CaN pathways, increased Ca2+i in β-cells activates other proteins and signaling cascades, including the MAP kinase pathway. This is mediated through the activation of Ras-GEF and B-Raf via CaM [76] and CaN [77], [78], [79], respectively, and results in activation of p42/44 (ERK1/2) [80]. Additionally, both p38 MAPK [81] and NF-κB [82] are activated by elevated Ca2+i in β-cells. CaMKII mediates the activation of NF-κB activation in β-cells through the phosphorylation of IκBα [82], a known target of CaMKII in neurons [83] (Figure 2). The temporal dynamics and sensitivity to Ca2+i of each of these pathways are not well defined in β-cells. While computational modeling predicts that increasing frequency of Ca2+i oscillations preferentially activates CaMKII over CaN [84], experimental data generated in β-cells are needed.
Figure 2.
Ca2+signaling pathways in β-cells. Following Ca2+ binding to Calmodulin (CaM), multiple downstream pathways are activated. CaM activates the Ca2+/Calmodulin-dependent protein kinase kinase (CaMKK) as well as members of the Ca2+/Calmodulin-dependent protein kinases (CaMK). Ca2+/CaM-bound CaMKK can phosphorylate and activate CaMKIV (A). Ca2+-bound CaM also activates the phosphatase Calcineurin (CaN) (B), which removes phosphate groups from CREB regulated transcription coactivator 2 (CRTC2) and nuclear factor of activated T cells (NFAT) proteins, resulting in their nuclear localization. CRTC2 can be inactivated through phosphorylation by microtubule affinity regulating kinase 2 (MARK2) and salt inducible kinase 2 (SIK2) (C), and NFAT can be inactivated by the kinases GSK3B and DYRK1A (D). Ca2+ results in the activation of p44/p42 (ERK1/2) or the MAP kinase pathway through the stimulation of Ras-GRF by CaM and the dephosphorylation of Raf by CaN (E). The NF-κB pathway can also be activated by Ca2+ in β-cells through the phosphorylation of IκB, which releases the p50 and p65 subunits (F). The upstream activation of various CaMKs and members of the MAP kinase pathway result in the phosphorylation and activation of cAMP response element binding (CREB) (G).
The disparate pathways active by elevated Ca2+i suggest that Ca2+ is a central mediator of many different cellular processes within the β-cell. Indeed, the study of the mediators and effectors of these Ca2+ signaling pathways demonstrates their importance in maintaining β-cell function and glucose homeostasis.
4. The role of Ca2+ in insulin production and secretion
During periods of elevated metabolic demand, β-cells must increase the production of insulin to ensure adequate insulin stores are maintained. As such, high glucose exposure increases insulin production in rat islets [85]. Influx of extracellular Ca2+ is critical for this process, as blocking L-VGCCs with verapamil ameliorates glucose-mediated insulin transcription [86]. The Ca2+-mediated promotion of insulin transcription can be separated into NFAT- and CaMK-dependent pathways. The rat insulin 1 promoter contains multiple NFAT binding sites [87], and NFATC2 is enriched at the insulin promoter following high glucose exposure in MIN6 cells and human islets [88]. Please note, immortalized β-cell lines have abnormal rates of apoptosis and replication and likely have abnormal activation of Ca2+ signaling pathways; therefore, conclusions derived from cell lines should be verified in primary cells. Furthermore, inhibiting NFAT with the CaN inhibitor tacrolimus (FK-506) abrogates the glucose-mediated increase in insulin promoter activity in INS-1 cells [87]. NFAT proteins are also sufficient to increase insulin gene expression, since a β-cell specific doxycycline-responsive constitutively active NFATC2 significantly increases Ins1 and Ins2 gene expression in vivo [89].
Besides NFAT, CaMKIV is also required to induce insulin expression, as shown by transfection of INS-1 cells with a kinase-dead CaMKIV, which blocks glucose-mediated elevations in insulin promoter activity [61]. Conversely, overexpression of constitutively active CaMKIV significantly increases insulin gene expression in INS-1 cells [61]. CaMKIV may promote insulin expression through the actions of the transcription factors ATF2 (CREB2) and EGR1. Both ATF2 and EGR1 are positively regulated by Ca2+ in CaMKIV- and SRF-dependent manners, respectively, and overexpression of either factor is sufficient to increase insulin promoter activity [90], [91], [92]. The promotion of insulin production downstream of NFAT and CaMK pathway activation creates a system wherein Ca2+, acting as a stimulus for insulin secretion and also a signal to increase insulin synthesis, ensures adequate insulin levels during prolonged stimulation. In addition to the transcriptional regulation of insulin by members of Ca2+ signaling pathways, elevated glucose also increases rates of insulin mRNA translation [93] and stabilizes insulin mRNA [94]. However, the role of Ca2+ signaling pathway members in these processes is unknown.
While increases in Ca2+i are required for insulin granule fusion to the plasma membrane, activation of Ca2+ signaling pathways also promotes insulin secretion through CaMK- and CaN-dependent pathways. The importance of Ca2+ signaling pathways in promoting insulin secretion is observed in mouse models wherein diminished activity or expression of CaMKII [95], CREB [96], CaM [97] or CRTC2 [98] in mouse β-cells impairs insulin secretion and systemic glucose homeostasis. Furthermore, pharmacological inhibition of CaN with either FK-506 or cyclosporin A decreases insulin secretion in human islets [99], [100], while overexpression of NFATC1 and NFATC2 increases glucose- and KCl-stimulated insulin secretion in mouse islets [101]. These in vitro and in vivo models all support a critical role for members of Ca2+ signaling pathways in the promotion of insulin secretion.
One mechanism through which Ca2+ signaling promotes insulin secretion is through the formation β-cell “metabolic memory”, wherein repeated exposure to elevated glucose primes β-cells to significantly increase insulin secretion during an ensuing high glucose exposure [102]. Inhibiting CaMKII activity with KN93 abrogates the augmentation of insulin secretion during the secondary glucose challenge, suggesting a critical role for this kinase in the formation of a metabolic memory [102]. While the precise mediators which form the β-cell metabolic memory have not been elucidated, repeated high glucose exposure increases the expression of glucokinase, SNAP25, and MAFA. Additionally, phosphorylation levels of Synapsin I, a direct target of CaMKII, are increased following repeated high glucose exposure [103].
Ca2+ signaling may also promote insulin secretion by elevating mitochondrial activity through a process termed “Ca2+-metabolic coupling”. Periods of elevated insulin secretion require increased mitochondrial activity to replenish the ATP stores that sustain ATP-mediated membrane depolarization and insulin release. Influx of Ca2+ and downstream activation of CaMKs is required for this prolonged elevation in mitochondrial function, as inhibiting L-VGCCs or CaMKs blocks increased oxygen consumption rate (OCR; a measure of mitochondrial function) [104], [105], [106]. Furthermore, directly stimulating L-VGCCs with BayK8644 increases β-cell OCR, demonstrating the tight coupling of Ca2+i with mitochondrial function [105].
These studies establish that, in addition to Ca2+-mediated insulin vesicle fusion, activation of CaN/NFAT and CaMK also promote insulin secretion by increasing mitochondrial respiration and priming the β-cell under repeated high glucose exposures.
5. The role of Ca2+ in β-cell replication
Increased rates of β-cell proliferation are one adaptive mechanism β-cells employ to compensate for elevated metabolic demand and ensure euglycemia is maintained. Both in vitro [107] and in vivo studies [108], [109] have observed that increased β-cell proliferation in response to elevated glucose concentrations and Ca2+ signaling is critical for this process. Pharmacologic stimulation of glucokinase also increases β-cell replication [110], [111], which can be blocked by inhibiting membrane depolarization with diazoxide [110], suggesting that Ca2+ influx, as opposed to glucose metabolism alone, is necessary. Furthermore, increasing Ca2+i with the L-VGCC agonist, BayK8644, induces rat β-cell proliferation [112], [113], providing additional support for the role of Ca2+ signaling pathways in promoting β-cell proliferation.
Both CaMK- and NFAT-dependent mechanisms mediate the mitogenic effects of elevated Ca2+i in β-cells. Blocking CaMK activity with KN62 abrogates the glucose-mediated increase in β-cell proliferation [114]. Additionally, overexpression of constitutively active CaMKIV or dominant-negative CaMKIV significantly elevates or diminishes β-cell proliferative rates, respectively [114]. Downstream of CaMKIV, CREB activity is also required, as co-expression of a dominant-negative CREB can abrogate the mitogenic effects of CaMKIV overexpression and the CREB targets Irs2 and Nr4a1 promote β-cell proliferation [69], [107], [114], [115], [116], [117]. In sum, these data suggest that the CaMKIV/CREB/Irs2 and Nr4a1 pathway is one mechanism by which elevations in Ca2+i promote β-cell replication.
NFAT proteins also promote β-cell replication. Islets from juveniles (age 0.5 to nine years old) have higher proliferation rates associated with higher expression of NFATC1, NFATC2, and NFATC4 than islets from adults (20 years or older) [118]. Additionally, the expression of a doxycycline-mediated constitutively nuclear NFATC2 in mice increases β-cell proliferation rates 2-fold in vivo [89]. Within cultured human islets, overexpression of constitutively active NFATC1 or NFATC2 increases proliferation rates by 2- and 3-fold, respectively [101]. In support of the proliferative role of NFAT proteins in β-cells, two unbiased small molecule screens identified β-cell mitogens that act by inhibiting the NFAT kinases DYRK1A and GSK3β, thus increasing NFAT activity [112], [119]. These small molecule screens have been validated by an independent study, which found that the small molecule 5-iodotubercidin inhibits multiple DYRK family members and induces human β-cell proliferation through a CaN-dependent pathway [120]. Finally, increases in CaN activity may mediate the proliferative effects of the GLP-1 receptor agonist, exendin-4, on β-cells. Exendin-4-treated human islets have a 2-fold increase in proliferation rates and an associated significant increase in NFATC1, NFATC3, and NFATC4 expression. Inhibition of CaN with FK-506 abrogated exendin-4-mediated increases in NFAT gene expression level and β-cell proliferation rates [118]. Mechanistically, NFAT proteins transcriptionally regulate a large number of cell cycle and mitogenic genes in β-cells [101], including direct induction of Irs2 [121], [122], Ccdn1, and Cdk4 [89], which may all promote β-cell proliferation.
Similar to the positive effect of Ca2+ signaling pathways on insulin production, elevated β-cell proliferation rates during periods of increased systemic insulin demand allow for appropriate β-cell compensation and ensure appropriate β-cell functional capacity to maintain euglycemia.
6. The role of Ca2+ in β-cell survival
Ca2+ signaling pathways also promote β-cell viability and survival. MIN6 cells incubated for 24 h in high glucose (25 mM) have significantly reduced rates of apoptosis compared to MIN6 incubated in low glucose (5 mM) concentrations [123]. The cytoprotective effects of elevated glucose are blocked by inhibiting depolarization with diazoxide or Ca2+ influx with nifedipine [123]. Both CaN- and CaMK-dependent pathways have been suggested to mediate the pro-survival effects of Ca2+.
Inhibition of CaN with either FK-506 or cyclosporine A induces β-cell apoptosis in human islets in vitro [100], and FK-506 treatment of diabetic mice transplanted with human islets impairs graft function and glucose homeostasis [100], [124]. Examination of pancreatic biopsies from individuals receiving either cyclosporine A or FK-506 as an immunosuppressant display cellular evidence of β-cell apoptosis [125]. Finally, use of CaN inhibitors FK-506, cyclosporine A, and sirolimus as immunosuppressants in solid organ transplant is associated with the development of impaired glucose homeostasis and diabetes [126], [127]. These results suggest that CaN activity is required for β-cell survival.
In addition to the role of NFAT proteins, the CaMKIV/CREB pathway also promotes β-cell viability. MIN6 cells incubated in 12.5 mM glucose have significantly reduced caspase-3 activity compared to MIN6 incubated in 2.5 mM glucose [114]. CaMKIV may mediate these effects, as expression of a constitutively active CaMKIV reduces β-cell apoptosis rates and co-expression of a dominant-negative CREB is sufficient to block the cytoprotective effects of increased CaMKIV activity [114]. Supporting the role of CREB in promoting β-cell viability, in vivo studies show that transgenic expression of a dominant-negative CREB (A-CREB) in β-cells increases apoptosis and results in diabetes in mice [68], and in vitro studies demonstrate knockdown of CREB in INS-1 cells increased levels of cleaved caspase-3 [128]. CREB may promote β-cell viability through induction of cytoprotective factors Irs2 and Npas4, which both protect β-cells from stress and cell death [68], [129], [130].
In addition to the ability of elevated Ca2+i to promote β-cell viability, decreased Ca2+i also adversely impacts β-cell survival by impairing ER and mitochondrial Ca2+ handling. Depletion of ER Ca2+ results in ER stress and β-cell apoptosis [131], [132], [133]. Mechanistically, during states of low β-cell Ca2+i, such as low glucose exposure, ER Ca2+ depletion occurs due to inactivation of the sarcoplasmic endoplasmic reticulum Ca2+ ATPase (SERCA) and the ensuing lack of ER Ca2+ uptake [134]. Ca2+i is also intricately connected to mitochondrial function, as the activity of several mitochondrial enzymes depends on Ca2+ [135]. Mitochondrial Ca2+ uptake follows depolarization-dependent increases in Ca2+i, and ATP production increases as a consequence [136], [137]. Thus, decreases in Ca2+i are predicted to decrease mitochondrial activity, ATP production and SERCA action; and in so doing promote ER Ca2+ depletion, ER stress and β-cell death.
7. Ca2+ signaling pathways in T2D
As outlined above, Ca2+ signaling pathways have critical roles in regulating β-cell function, proliferation and viability; all processes that fail during the development of T2D. Despite this importance, only few members of Ca2+ signaling pathways have appeared as susceptibility loci in T2D GWAS studies [138], including the likely causal CDC123/CAMK1D locus [139], [140] and CAMKK2 variants [141]. However, a recent analysis of regulatory elements upstream of T2D susceptibility genes identified NFATC2 as a regulatory factor for 40% of genes identified through GWAS [101]. Furthermore, overexpression of NFATC1 or NFATC2 in human islets significantly alters the expression of a number of T2D susceptibility genes including KLF11, HHEX, and PROX1 [101]. While the genetic link between Ca2+ signaling pathways and T2D requires further examination, research using animal models and clinical data support a role for impaired Ca2+ signaling in β-cell failure during T2D pathogenesis.
The prediabetic milieu, characterized by increased glucose and fatty acids levels, results in increased β-cell depolarization, Ca2+ influx, and insulin secretion to maintain euglycemia. Short-term stimulation of Ca2+ signaling pathways yields positive effects for the β-cell (insulin production, secretion, replication and viability). In contrast, chronic stimulation of these pathways has deleterious effects. This is observed in multiple rodent models in which members of Ca2+ signaling pathways are overexpressed. For instance, overexpression of a constitutively active CaN increases β-cell apoptosis, decreases proliferation, and results in glucose intolerance [142]. Similarly, mice that overexpress a constitutively active CaMKIIα in β-cells also develop diabetes associated with decreased β-cell mass [143]. CaM overexpression in mouse β-cells also leads to diabetes [144]. In this CaM overexpression model, there is also a loss of insulin-expressing cells with a concomitant increase in islet cells expressing glucagon, perhaps due to β-cell transdifferentiation into α-cells [144]. The observations from mouse models suggest chronic activation of Ca2+ signaling pathways impairs β-cell function, which is supported by human studies in which individuals with T2D are treated with diazoxide to inhibit β-cell depolarization. After a multi-day treatment period, insulin secretion is improved [145], [146]. This model of pathogenic Ca2+ flux may also explain why sulphonylureas initially improve, but ultimately worsen, glycemic control in individuals with T2D [147].
Chronically elevated Ca2+i may drive β-cell dysfunction and failure by exacerbating ER stress and β-cell differentiation. β-cell ER stress is sufficient to cause diabetes in mice [148], has been observed in individuals with T2D [149], and relies on activation of Ca2+ signaling pathways [4]. Treatment with a combination of high glucose and palmitate results in stark activation of ER stress and increases rates of β-cell apoptosis in both immortalized β-cell lines and primary islets [150], [151]. However, blocking depolarization with diazoxide [150] or Ca2+ influx with nifedipine [151] protects against the induction of ER stress and subsequent apoptosis of β-cells.
In addition to exacerbation of ER stress, chronically active Ca2+ signaling also results in loss of β-cell maturation. Models in which β-cells are exposed to chronically elevated glucose levels and increased Ca2+i result in the loss of β-cell maturation; such as the db/db or Akita mouse, a diphtheria toxin-mediated β-cell ablation model, insulin receptor antagonism [152], or genetic removal of insulin genes from β-cells [153]. Furthermore, inhibiting β-cell depolarization in the db/db mouse, by crossing it to a β-cell specific constitutively active Kir6.2 mutant, significantly reduces rates of β-cell transdifferentiation into gastrin-expressing cells compared to db/db controls, despite no improvement in glucose handling [152]. This experiment strongly suggests that β-cell depolarization, and not hyperglycemia alone, is required to drive β-cell dedifferentiation. This hypothesis is supported by an in vitro transdifferentiation model in which mouse islets are cultured at either 5 mM or 25 mM glucose. After 2 days in culture, islets exposed to high glucose have a significant increase in gastrin expression, which could be abrogated by co-culture with either diazoxide, nifedipine or FK-506 [152], demonstrating that Ca2+ influx and CaN activity are also required for this process. Importantly, islets from individuals with T2D have significantly increased numbers of gastrin-expressing cells; although it remains unknown whether aberrant Ca2+ signaling is the cause [152].
The role of Ca2+ signaling in driving β-cell transdifferentiation is further supported by data from the β-cell Abcc8 knockout mouse. Deletion of Abcc8, a subunit of the KATP channel, from β-cells increases intracellular Ca2+ most notably under low glucose conditions, but also under high glucose exposure [154]. This is accompanied by the loss of β-cell maturation status and transdifferentiation into PP-cells, despite an absence of frank hyperglycemia [154]. Additionally, expression of the dedifferentiation marker Aldh1a3 is significantly increased in the Abcc8 null mouse and can be largely normalized by blocking Ca2+ influx with verapamil [154]. In contrast to other dedifferentiation models, which present with profound hyperglycemia, this Abcc8 null model decouples hyperglycemia from increased Ca2+ influx and elegantly demonstrates that chronically active Ca2+ signaling pathways are sufficient to promote β-cell dedifferentiation.
These studies define a clear role for Ca2+ signaling pathways in driving β-cell dedifferentiation and transdifferentiation and support a model in which chronic activation of Ca2+ signaling pathways results in increased stress and a loss of β-cell maturation status that contributes to β-cell failure in T2D. Less certain, however, is the role of altered Ca2+ handling in the development of type 1 diabetes (T1D). In vitro models of cytokine treatment show impaired β-cell Ca2+ handling following exposure to proinflammatory cytokines, including reduced oscillatory Ca2+ fluctuations [155] and impaired glucose-stimulated Ca2+ influx [156]. Additionally, blockage of L-VGCCs protects mice from diabetes and β-cell loss in low-dose STZ-induced diabetes [157]. However, further assessments in T1D models such as the non-obese diabetic mouse may bring further illumination as to the role of Ca2+-regulated cell death in T1D.
8. Conclusions and future directions
In the postprandial state, β-cells undergo waves of depolarization and Ca2+ influx, which activates multiple downstream signaling pathways. Stimulation of these pathways promotes insulin production and secretion, proliferation, and viability. The importance of Ca2+ signaling in β-cells is evidenced by the β-cell dysfunction and impairment in systemic glucose homeostasis that results from inhibiting the activity of various members of the Ca2+ signaling cascade, including CREB [68], [96], CaN [89], and CaMKII [95]. Conversely, overstimulation of these pathways (a summary of mouse models in Table 1), as is observed under chronic hyperglycemia, also results in β-cell dysfunction and loss of β-cell differentiation status. This is in line with observations from mouse models that specifically overexpress CaN [142], CaMKII [143], or CaM [144], [158], which impairs β-cell function, maturation status, and viability. Together, these studies underscore the requirement for tight control over Ca2+i and the downstream pathways it regulates in β-cells.
Table 1.
Mouse models of Ca2+-related diabetes.
| Target gene | Model | Phenotype | Reference(s) |
|---|---|---|---|
| Models of decreased expression/activity | |||
| Calm1 | Transgenic OE of inactive Calm1 (CaM-8) | Reduced insulin secretion resulting in diabetes | [97] Ribar et al., 1995 |
| Camk2 (a,b,d,g) | Tetracycline-mediated OE of Camk2 pseudosubstrate inhibitory peptide (EAC3I) | Reduced insulin secretion and impaired glucose tolerance | [95] Dadi et al., 2014 |
| Creb1 | Transgenic OE of DN Creb1 (A-CREB) | Increased apoptosis resulting in diabetes | [68] Jhala et al., 2003 |
| Pdx1-CreERTg-mediated deletion | Females on HFD glucose intolerant (not observed in males) | [96] Shin et al., 2014 | |
| Crtc2 | MIP-CreER-mediated deletion | Reduced insulin secretion and glucose intolerance | [98] Blanchet et al., 2015 |
| Ppp3r1 | Ins2-CreTg-mediated deletion of calcineurin b1 | Diabetes after 10 weeks | [89] Heit et al., 2006 |
| Nr4a1 | Germline deletion | Reduced β-cell proliferation | [117] Tessem et al., 2014 |
| Abcc8 | Ins2-CreTg-mediated deletion | β-cell transdifferentation into PP-cells | [154] Stancill et al., 2017 |
| Models of increased expression/activity | |||
| Calm1 | Transgenic OE of chicken Calm1 in β-cells | Increased apoptosis, possible transdifferentiation resulting in diabetes | [144] Epstein et al., 1989 |
| [158] Yu et al., 2002 | |||
| Camk2a | Transgenic OE in β-cells | Increased apoptosis, decreased proliferation resulting in diabetes | [143] Kato et al., 2008 |
| Nfatc1 | Doxycycline-inducible transgenic OE of constitutively active Nfatc1 (Nfatc1nuc) | Increased Pdx1, Glut2, and β-cell proliferation | [89] Heit et al., 2006 |
| Ppp3ca | Transgenic OE of constitutively active calcineurin A in β-cells | Reduced proliferation/increased apoptosis resulting in diabetes | [142] Bernal-Mizrachi et al., 2010 |
Summary of mouse models of diabetes or β-cell dysfunction following overexpression (OE) or deletion of Ca2+-related genes. DN = dominant-negative; HFD = high fat diet; Tg = transgenic.
While current studies have observed disrupted β-cell Ca2+ handling in mouse models [159], [160] and in humans with T2D [125], [126], [127], [161], there are several avenues of research which offer greater understanding of the pathogenic role of altered Ca2+ signaling in the β-cell. These include a further characterization of how altered Ca2+ signaling impacts β-cell transcriptomics, ER and mitochondrial function, and defining the nature of the altered Ca2+ handling by the β-cell under pathologic conditions, particularly by important Ca2+ stores such as ER and mitochondria. Finally, it will be important to determine if and how Ca2+ signaling pathways are impaired in β-cells from individuals with T2D and whether these pathways can be therapeutically targeted.
Acknowledgements
F.C.L., P.V.S. and T.S. wrote and edited the manuscript.
This work was supported by an operating grant to F.C.L. from the CIHR (MOP 142222). Salary support to F.C.L. was provided by the Michael Smith Foundation for Health Research (#5238 BIOM), the Diabetes Canada, and the BC Children's Hospital Research Institute. Fellowship support was provided by the CIHR-BC Transplantation Trainee Program (T.S.), UBC 4YF (P.V.S.) and the Diabetes Canada (P.V.S.). We thank members of the Lynn Lab for critical reading of the manuscript and peer reviewers for their insightful feedback. While every effort was made to make this review as comprehensive as possible, there undoubtedly is excellent research that was excluded due to length constraints.
Conflict of interest
None declared.
References
- 1.Berridge M.J., Bootman M.D., Roderick H.L. Calcium signalling: dynamics, homeostasis and remodelling. Nature Reviews Molecular Cell Biology. 2003;4:517–529. doi: 10.1038/nrm1155. [DOI] [PubMed] [Google Scholar]
- 2.Swami M. Metabolism: calcium-mediated control. Nature Medicine. 2012;18 670–670. [Google Scholar]
- 3.Ozcan L., Tabas I. CaMKII in cardiometabolic disease. Aging (Albany NY) 2014;6:430–431. doi: 10.18632/aging.100675. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Timmins J.M., Ozcan L., Seimon T.A., Li G., Malagelada C., Backs J. Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways. Journal of Clinical Investigation. 2009;119:2925–2941. doi: 10.1172/JCI38857. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Gilon P., Chae H.Y., Rutter G.A., Ravier M.A. Calcium signaling in pancreatic beta-cells in health and in type 2 diabetes. Cell Calcium. 2014;56:340–361. doi: 10.1016/j.ceca.2014.09.001. [DOI] [PubMed] [Google Scholar]
- 6.Braun M., Ramracheya R., Bengtsson M., Zhang Q., Karanauskaite J., Partridge C. Voltage-gated ion channels in human pancreatic beta-cells: electrophysiological characterization and role in insulin secretion. Diabetes. 2008;57:1618–1628. doi: 10.2337/db07-0991. [DOI] [PubMed] [Google Scholar]
- 7.Prentki M., Matschinsky F.M., Madiraju S.R. Metabolic signaling in fuel-induced insulin secretion. Cell Metabolism. 2013;18:162–185. doi: 10.1016/j.cmet.2013.05.018. [DOI] [PubMed] [Google Scholar]
- 8.Fuller M.D., Emrick M.A., Sadilek M., Scheuer T., Catterall W.A. Molecular mechanism of calcium channel regulation in the fight-or-flight response. Science Signaling. 2010;3:ra70. doi: 10.1126/scisignal.2001152. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Wu Y., Shyng S.L., Chen P.C. Concerted trafficking regulation of Kv2.1 and KATP channels by leptin in pancreatic beta-cells. Journal of Biological Chemistry. 2015;290:29676–29690. doi: 10.1074/jbc.M115.670877. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Dezaki K., Hosoda H., Kakei M., Hashiguchi S., Watanabe M., Kangawa K. Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2+ signaling in beta-cells: implication in the glycemic control in rodents. Diabetes. 2004;53:3142–3151. doi: 10.2337/diabetes.53.12.3142. [DOI] [PubMed] [Google Scholar]
- 11.Gibson T.B., Lawrence M.C., Gibson C.J., Vanderbilt C.A., McGlynn K., Arnette D. Inhibition of glucose-stimulated activation of extracellular signal-regulated protein kinases 1 and 2 by epinephrine in pancreatic beta-cells. Diabetes. 2006;55:1066–1073. doi: 10.2337/diabetes.55.04.06.db05-1266. [DOI] [PubMed] [Google Scholar]
- 12.Gilon P., Henquin J.C. Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. Endocrine Reviews. 2001;22:565–604. doi: 10.1210/edrv.22.5.0440. [DOI] [PubMed] [Google Scholar]
- 13.Prins D., Michalak M. Organellar calcium buffers. Cold Spring Harbor Perspectives in Biology. 2011;3 doi: 10.1101/cshperspect.a004069. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Contreras L., Drago I., Zampese E., Pozzan T. Mitochondria: the calcium connection. Biochimica et Biophysica Acta. 2010;1797:607–618. doi: 10.1016/j.bbabio.2010.05.005. [DOI] [PubMed] [Google Scholar]
- 15.Johnson J.D., Misler S. Nicotinic acid-adenine dinucleotide phosphate-sensitive calcium stores initiate insulin signaling in human beta cells. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:14566–14571. doi: 10.1073/pnas.222099799. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Borge P.D., Moibi J., Greene S.R., Trucco M., Young R.A., Gao Z. Insulin receptor signaling and sarco/endoplasmic reticulum calcium ATPase in beta-cells. Diabetes. 2002;51(Suppl 3):S427–S433. doi: 10.2337/diabetes.51.2007.s427. [DOI] [PubMed] [Google Scholar]
- 17.Mancini A.D., Poitout V. The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends in Endocrinology and Metabolism. 2013;24:398–407. doi: 10.1016/j.tem.2013.03.003. [DOI] [PubMed] [Google Scholar]
- 18.Suzuki T., Imai J., Yamada T., Ishigaki Y., Kaneko K., Uno K. Interleukin-6 enhances glucose-stimulated insulin secretion from pancreatic beta-cells: potential involvement of the PLC-IP3-dependent pathway. Diabetes. 2011;60:537–547. doi: 10.2337/db10-0796. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Sasaki S., Nakagaki I., Kondo H., Hori S. Involvement of the ryanodine-sensitive Ca2+ store in GLP-1-induced Ca2+ oscillations in insulin-secreting HIT cells. Pflügers Archiv. 2002;445:342–351. doi: 10.1007/s00424-002-0965-z. [DOI] [PubMed] [Google Scholar]
- 20.Lu M., Wheeler M.B., Leng X.H., Boyd A.E., 3rd The role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I(7-37) Endocrinology. 1993;132:94–100. doi: 10.1210/endo.132.1.8380389. [DOI] [PubMed] [Google Scholar]
- 21.Gromada J., Dissing S., Bokvist K., Renstrom E., Frokjaer-Jensen J., Wulff B.S. Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting beta TC3-cells by enhancement of intracellular calcium mobilization. Diabetes. 1995;44:767–774. doi: 10.2337/diab.44.7.767. [DOI] [PubMed] [Google Scholar]
- 22.Kim B.J., Park K.H., Yim C.Y., Takasawa S., Okamoto H., Im M.J. Generation of nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose by glucagon-like peptide-1 evokes Ca2+ signal that is essential for insulin secretion in mouse pancreatic islets. Diabetes. 2008;57:868–878. doi: 10.2337/db07-0443. [DOI] [PubMed] [Google Scholar]
- 23.MacDonald P.E., El-Kholy W., Riedel M.J., Salapatek A.M., Light P.E., Wheeler M.B. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes. 2002;51(Suppl 3):S434–S442. doi: 10.2337/diabetes.51.2007.s434. [DOI] [PubMed] [Google Scholar]
- 24.Ross C.A., Meldolesi J., Milner T.A., Satoh T., Supattapone S., Snyder S.H. Inositol 1,4,5-trisphosphate receptor localized to endoplasmic reticulum in cerebellar Purkinje neurons. Nature. 1989;339:468–470. doi: 10.1038/339468a0. [DOI] [PubMed] [Google Scholar]
- 25.Micaroni M., Mironov A.A. Roles of Ca and secretory pathway Ca-ATPase pump type 1 (SPCA1) in intra-Golgi transport. Communicative & Integrative Biology. 2010;3:504–507. doi: 10.4161/cib.3.6.13211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Pinton P., Pozzan T., Rizzuto R. The Golgi apparatus is an inositol 1,4,5-trisphosphate-sensitive Ca2+ store, with functional properties distinct from those of the endoplasmic reticulum. The EMBO Journal. 1998;17:5298–5308. doi: 10.1093/emboj/17.18.5298. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Burant C.F. Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes. Diabetes Care. 2013;36(Suppl 2):S175–S179. doi: 10.2337/dcS13-2037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Thore S., Dyachok O., Tengholm A. Oscillations of phospholipase C activity triggered by depolarization and Ca2+ influx in insulin-secreting cells. Journal of Biological Chemistry. 2004;279:19396–19400. doi: 10.1074/jbc.C400088200. [DOI] [PubMed] [Google Scholar]
- 29.Thore S., Dyachok O., Gylfe E., Tengholm A. Feedback activation of phospholipase C via intracellular mobilization and store-operated influx of Ca2+ in insulin-secreting beta-cells. Journal of Cell Science. 2005;118:4463–4471. doi: 10.1242/jcs.02577. [DOI] [PubMed] [Google Scholar]
- 30.Masgrau R., Churchill G.C., Morgan A.J., Ashcroft S.J., Galione A. NAADP: a new second messenger for glucose-induced Ca2+ responses in clonal pancreatic beta cells. Current Biology. 2003;13:247–251. doi: 10.1016/s0960-9822(03)00041-1. [DOI] [PubMed] [Google Scholar]
- 31.Cosker F., Cheviron N., Yamasaki M., Menteyne A., Lund F.E., Moutin M.J. The ecto-enzyme CD38 is a nicotinic acid adenine dinucleotide phosphate (NAADP) synthase that couples receptor activation to Ca2+ mobilization from lysosomes in pancreatic acinar cells. Journal of Biological Chemistry. 2010;285:38251–38259. doi: 10.1074/jbc.M110.125864. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Mitchell K.J., Lai F.A., Rutter G.A. Ryanodine receptor type I and nicotinic acid adenine dinucleotide phosphate receptors mediate Ca2+ release from insulin-containing vesicles in living pancreatic beta-cells (MIN6) Journal of Biological Chemistry. 2003;278:11057–11064. doi: 10.1074/jbc.M210257200. [DOI] [PubMed] [Google Scholar]
- 33.Calcraft P.J., Ruas M., Pan Z., Cheng X., Arredouani A., Hao X. NAADP mobilizes calcium from acidic organelles through two-pore channels. Nature. 2009;459:596–600. doi: 10.1038/nature08030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Cane M.C., Parrington J., Rorsman P., Galione A., Rutter G.A. The two pore channel TPC2 is dispensable in pancreatic beta-cells for normal Ca(2)(+) dynamics and insulin secretion. Cell Calcium. 2016;59:32–40. doi: 10.1016/j.ceca.2015.12.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Arredouani A., Ruas M., Collins S.C., Parkesh R., Clough F., Pillinger T. Nicotinic acid adenine dinucleotide phosphate (NAADP) and endolysosomal two-pore channels modulate membrane excitability and stimulus-secretion coupling in mouse pancreatic beta cells. Journal of Biological Chemistry. 2015;290:21376–21392. doi: 10.1074/jbc.M115.671248. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Kato I., Yamamoto Y., Fujimura M., Noguchi N., Takasawa S., Okamoto H. CD38 disruption impairs glucose-induced increases in cyclic ADP-ribose, [Ca2+]i, and insulin secretion. Journal of Biological Chemistry. 1999;274:1869–1872. doi: 10.1074/jbc.274.4.1869. [DOI] [PubMed] [Google Scholar]
- 37.Johnson J.D., Kuang S., Misler S., Polonsky K.S. Ryanodine receptors in human pancreatic beta cells: localization and effects on insulin secretion. The FASEB Journal. 2004;18:878–880. doi: 10.1096/fj.03-1280fje. [DOI] [PubMed] [Google Scholar]
- 38.Lanner J.T., Georgiou D.K., Joshi A.D., Hamilton S.L. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harbor Perspectives in Biology. 2010;2:a003996. doi: 10.1101/cshperspect.a003996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Dixit S.S., Wang T., Manzano E.J., Yoo S., Lee J., Chiang D.Y. Effects of CaMKII-mediated phosphorylation of ryanodine receptor type 2 on islet calcium handling, insulin secretion, and glucose tolerance. PLoS One. 2013;8 doi: 10.1371/journal.pone.0058655. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Dror V., Kalynyak T.B., Bychkivska Y., Frey M.H., Tee M., Jeffrey K.D. Glucose and endoplasmic reticulum calcium channels regulate HIF-1beta via presenilin in pancreatic beta-cells. Journal of Biological Chemistry. 2008;283:9909–9916. doi: 10.1074/jbc.M710601200. [DOI] [PubMed] [Google Scholar]
- 41.Varadi A., Rutter G.A. Dynamic imaging of endoplasmic reticulum Ca2+ concentration in insulin-secreting MIN6 Cells using recombinant targeted cameleons: roles of sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA)-2 and ryanodine receptors. Diabetes. 2002;51(Suppl 1):S190–S201. doi: 10.2337/diabetes.51.2007.s190. [DOI] [PubMed] [Google Scholar]
- 42.Rosker C., Meur G., Taylor E.J., Taylor C.W. Functional ryanodine receptors in the plasma membrane of RINm5F pancreatic beta-cells. Journal of Biological Chemistry. 2009;284:5186–5194. doi: 10.1074/jbc.M805587200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Islam M.S. The ryanodine receptor calcium channel of beta-cells: molecular regulation and physiological significance. Diabetes. 2002;51:1299–1309. doi: 10.2337/diabetes.51.5.1299. [DOI] [PubMed] [Google Scholar]
- 44.Lee H.C. Cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate (NAADP) as messengers for calcium mobilization. Journal of Biological Chemistry. 2012;287:31633–31640. doi: 10.1074/jbc.R112.349464. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Wiederkehr A., Wollheim C.B. Impact of mitochondrial calcium on the coupling of metabolism to insulin secretion in the pancreatic beta-cell. Cell Calcium. 2008;44:64–76. doi: 10.1016/j.ceca.2007.11.004. [DOI] [PubMed] [Google Scholar]
- 46.Palty R., Silverman W.F., Hershfinkel M., Caporale T., Sensi S.L., Parnis J. NCLX is an essential component of mitochondrial Na+/Ca2+ exchange. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:436–441. doi: 10.1073/pnas.0908099107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Raffaello A., Mammucari C., Gherardi G., Rizzuto R. Calcium at the center of cell signaling: interplay between endoplasmic reticulum, mitochondria, and lysosomes. Trends in Biochemical Sciences. 2016;41:1035–1049. doi: 10.1016/j.tibs.2016.09.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Decuypere J.P., Monaco G., Bultynck G., Missiaen L., De Smedt H., Parys J.B. The IP(3) receptor-mitochondria connection in apoptosis and autophagy. Biochimica et Biophysica Acta. 2011;1813:1003–1013. doi: 10.1016/j.bbamcr.2010.11.023. [DOI] [PubMed] [Google Scholar]
- 49.Alam M.R., Groschner L.N., Parichatikanond W., Kuo L., Bondarenko A.I., Rost R. Mitochondrial Ca2+ uptake 1 (MICU1) and mitochondrial Ca2+ uniporter (MCU) contribute to metabolism-secretion coupling in clonal pancreatic beta-cells. Journal of Biological Chemistry. 2012;287:34445–34454. doi: 10.1074/jbc.M112.392084. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Quan X., Nguyen T.T., Choi S.K., Xu S., Das R., Cha S.K. Essential role of mitochondrial Ca2+ uniporter in the generation of mitochondrial pH gradient and metabolism-secretion coupling in insulin-releasing cells. Journal of Biological Chemistry. 2015;290:4086–4096. doi: 10.1074/jbc.M114.632547. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Johnson J.D., Bround M.J., White S.A., Luciani D.S. Nanospaces between endoplasmic reticulum and mitochondria as control centres of pancreatic beta-cell metabolism and survival. Protoplasma. 2012;249(Suppl 1):S49–S58. doi: 10.1007/s00709-011-0349-3. [DOI] [PubMed] [Google Scholar]
- 52.Laude A.J., Simpson A.W. Compartmentalized signalling: Ca2+ compartments, microdomains and the many facets of Ca2+ signalling. FEBS Journal. 2009;276:1800–1816. doi: 10.1111/j.1742-4658.2009.06927.x. [DOI] [PubMed] [Google Scholar]
- 53.Quesada I., Rovira J.M., Martin F., Roche E., Nadal A., Soria B. Nuclear KATP channels trigger nuclear Ca(2+) transients that modulate nuclear function. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:9544–9549. doi: 10.1073/pnas.142039299. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Hardingham G.E., Arnold F.J., Bading H. Nuclear calcium signaling controls CREB-mediated gene expression triggered by synaptic activity. Nature Neuroscience. 2001;4:261–267. doi: 10.1038/85109. [DOI] [PubMed] [Google Scholar]
- 55.Rutter G.A., Tsuboi T., Ravier M.A. Ca2+ microdomains and the control of insulin secretion. Cell Calcium. 2006;40:539–551. doi: 10.1016/j.ceca.2006.08.015. [DOI] [PubMed] [Google Scholar]
- 56.Wiederkehr A., Szanda G., Akhmedov D., Mataki C., Heizmann C.W., Schoonjans K. Mitochondrial matrix calcium is an activating signal for hormone secretion. Cell Metabolism. 2011;13:601–611. doi: 10.1016/j.cmet.2011.03.015. [DOI] [PubMed] [Google Scholar]
- 57.Shen X., Valencia C.A., Szostak J.W., Dong B., Liu R. Scanning the human proteome for calmodulin-binding proteins. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:5969–5974. doi: 10.1073/pnas.0407928102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Chin D., Means A.R. Calmodulin: a prototypical calcium sensor. Trends in Cell Biology. 2000;10:322–328. doi: 10.1016/s0962-8924(00)01800-6. [DOI] [PubMed] [Google Scholar]
- 59.Hoeflich K.P., Ikura M. Calmodulin in action: diversity in target recognition and activation mechanisms. Cell. 2002;108:739–742. doi: 10.1016/s0092-8674(02)00682-7. [DOI] [PubMed] [Google Scholar]
- 60.Wayman G.A., Tokumitsu H., Davare M.A., Soderling T.R. Analysis of CaM-kinase signaling in cells. Cell Calcium. 2011;50:1–8. doi: 10.1016/j.ceca.2011.02.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Yu X., Murao K., Sayo Y., Imachi H., Cao W.M., Ohtsuka S. The role of calcium/calmodulin-dependent protein kinase cascade in glucose upregulation of insulin gene expression. Diabetes. 2004;53:1475–1481. doi: 10.2337/diabetes.53.6.1475. [DOI] [PubMed] [Google Scholar]
- 62.Marcelo K.L., Ribar T., Means C.R., Tsimelzon A., Stevens R.D., Ilkayeva O. Research resource: roles for calcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in systems metabolism. Molecular Endocrinology. 2016;30:557–572. doi: 10.1210/me.2016-1021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Fogarty M.P., Cannon M.E., Vadlamudi S., Gaulton K.J., Mohlke K.L. Identification of a regulatory variant that binds FOXA1 and FOXA2 at the CDC123/CAMK1D type 2 diabetes GWAS locus. PLoS Genetics. 2014;10 doi: 10.1371/journal.pgen.1004633. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Segerstolpe A., Palasantza A., Eliasson P., Andersson E.M., Andreasson A.C., Sun X. Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes. Cell Metabolism. 2016;24:593–607. doi: 10.1016/j.cmet.2016.08.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Wang X., Li H., De Leo D., Guo W., Koshkin V., Fantus I.G. Gene and protein kinase expression profiling of reactive oxygen species-associated lipotoxicity in the pancreatic beta-cell line MIN6. Diabetes. 2004;53:129–140. doi: 10.2337/diabetes.53.1.129. [DOI] [PubMed] [Google Scholar]
- 66.Easom R.A. CaM kinase II: a protein kinase with extraordinary talents germane to insulin exocytosis. Diabetes. 1999;48:675–684. doi: 10.2337/diabetes.48.4.675. [DOI] [PubMed] [Google Scholar]
- 67.Kim T.K., Hemberg M., Gray J.M., Costa A.M., Bear D.M., Wu J. Widespread transcription at neuronal activity-regulated enhancers. Nature. 2010;465:182–187. doi: 10.1038/nature09033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Jhala U.S., Canettieri G., Screaton R.A., Kulkarni R.N., Krajewski S., Reed J. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes & Development. 2003;17:1575–1580. doi: 10.1101/gad.1097103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Persaud S.J., Liu B., Sampaio H.B., Jones P.M., Muller D.S. Calcium/calmodulin-dependent kinase IV controls glucose-induced Irs2 expression in mouse beta cells via activation of cAMP response element-binding protein. Diabetologia. 2011;54:1109–1120. doi: 10.1007/s00125-011-2050-7. [DOI] [PubMed] [Google Scholar]
- 70.Dalle S., Quoyer J., Varin E., Costes S. Roles and regulation of the transcription factor CREB in pancreatic beta-cells. Current Molecular Pharmacology. 2011;4:187–195. doi: 10.2174/1874467211104030187. [DOI] [PubMed] [Google Scholar]
- 71.Screaton R.A., Conkright M.D., Katoh Y., Best J.L., Canettieri G., Jeffries S. The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. Cell. 2004;119:61–74. doi: 10.1016/j.cell.2004.09.015. [DOI] [PubMed] [Google Scholar]
- 72.Jansson D., Ng A.C., Fu A., Depatie C., Al Azzabi M., Screaton R.A. Glucose controls CREB activity in islet cells via regulated phosphorylation of TORC2. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:10161–10166. doi: 10.1073/pnas.0800796105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Macian F. NFAT proteins: key regulators of T-cell development and function. Nature Reviews Immunology. 2005;5:472–484. doi: 10.1038/nri1632. [DOI] [PubMed] [Google Scholar]
- 74.Wu H., Rothermel B., Kanatous S., Rosenberg P., Naya F.J., Shelton J.M. Activation of MEF2 by muscle activity is mediated through a calcineurin-dependent pathway. The EMBO Journal. 2001;20:6414–6423. doi: 10.1093/emboj/20.22.6414. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Crabtree G.R., Schreiber S.L. SnapShot: Ca2+-calcineurin-NFAT signaling. Cell. 2009;138 doi: 10.1016/j.cell.2009.06.026. 210, 210 e211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Farnsworth C.L., Freshney N.W., Rosen L.B., Ghosh A., Greenberg M.E., Feig L.A. Calcium activation of Ras mediated by neuronal exchange factor Ras-GRF. Nature. 1995;376:524–527. doi: 10.1038/376524a0. [DOI] [PubMed] [Google Scholar]
- 77.Briaud I., Lingohr M.K., Dickson L.M., Wrede C.E., Rhodes C.J. Differential activation mechanisms of Erk-1/2 and p70(S6K) by glucose in pancreatic beta-cells. Diabetes. 2003;52:974–983. doi: 10.2337/diabetes.52.4.974. [DOI] [PubMed] [Google Scholar]
- 78.Duan L., Cobb M.H. Calcineurin increases glucose activation of ERK1/2 by reversing negative feedback. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:22314–22319. doi: 10.1073/pnas.1016630108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Lawrence M.C., McGlynn K., Park B.H., Cobb M.H. ERK1/2-dependent activation of transcription factors required for acute and chronic effects of glucose on the insulin gene promoter. Journal of Biological Chemistry. 2005;280:26751–26759. doi: 10.1074/jbc.M503158200. [DOI] [PubMed] [Google Scholar]
- 80.Frodin M., Sekine N., Roche E., Filloux C., Prentki M., Wollheim C.B. Glucose, other secretagogues, and nerve growth factor stimulate mitogen-activated protein kinase in the insulin-secreting beta-cell line, INS-1. Journal of Biological Chemistry. 1995;270:7882–7889. doi: 10.1074/jbc.270.14.7882. [DOI] [PubMed] [Google Scholar]
- 81.Macfarlane W.M., Smith S.B., James R.F., Clifton A.D., Doza Y.N., Cohen P. The p38/reactivating kinase mitogen-activated protein kinase cascade mediates the activation of the transcription factor insulin upstream factor 1 and insulin gene transcription by high glucose in pancreatic beta-cells. Journal of Biological Chemistry. 1997;272:20936–20944. doi: 10.1074/jbc.272.33.20936. [DOI] [PubMed] [Google Scholar]
- 82.Bernal-Mizrachi E., Wen W., Shornick M., Permutt M.A. Activation of nuclear factor-kappaB by depolarization and Ca(2+) influx in MIN6 insulinoma cells. Diabetes. 2002;51(Suppl 3):S484–S488. doi: 10.2337/diabetes.51.2007.s484. [DOI] [PubMed] [Google Scholar]
- 83.Meffert M.K., Chang J.M., Wiltgen B.J., Fanselow M.S., Baltimore D. NF-kappa B functions in synaptic signaling and behavior. Nature Neuroscience. 2003;6:1072–1078. doi: 10.1038/nn1110. [DOI] [PubMed] [Google Scholar]
- 84.Li L., Stefan M.I., Le Novere N. Calcium input frequency, duration and amplitude differentially modulate the relative activation of calcineurin and CaMKII. PLoS One. 2012;7 doi: 10.1371/journal.pone.0043810. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Alarcon C., Verchere C.B., Rhodes C.J. Translational control of glucose-induced islet amyloid polypeptide production in pancreatic islets. Endocrinology. 2012;153:2082–2087. doi: 10.1210/en.2011-2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.German M.S., Moss L.G., Rutter W.J. Regulation of insulin gene expression by glucose and calcium in transfected primary islet cultures. Journal of Biological Chemistry. 1990;265:22063–22066. [PubMed] [Google Scholar]
- 87.Lawrence M.C., Bhatt H.S., Easom R.A. NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1. Diabetes. 2002;51:691–698. doi: 10.2337/diabetes.51.3.691. [DOI] [PubMed] [Google Scholar]
- 88.Lawrence M.C., Borenstein-Auerbach N., McGlynn K., Kunnathodi F., Shahbazov R., Syed I. NFAT targets signaling molecules to gene promoters in pancreatic beta-cells. Molecular Endocrinology. 2015;29:274–288. doi: 10.1210/me.2014-1066. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Heit J.J., Apelqvist A.A., Gu X., Winslow M.M., Neilson J.R., Crabtree G.R. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature. 2006;443:345–349. doi: 10.1038/nature05097. [DOI] [PubMed] [Google Scholar]
- 90.Ban N., Yamada Y., Someya Y., Ihara Y., Adachi T., Kubota A. Activating transcription factor-2 is a positive regulator in CaM kinase IV-induced human insulin gene expression. Diabetes. 2000;49:1142–1148. doi: 10.2337/diabetes.49.7.1142. [DOI] [PubMed] [Google Scholar]
- 91.Eto K., Kaur V., Thomas M.K. Regulation of insulin gene transcription by the immediate-early growth response gene Egr-1. Endocrinology. 2006;147:2923–2935. doi: 10.1210/en.2005-1336. [DOI] [PubMed] [Google Scholar]
- 92.Bernal-Mizrachi E., Wice B., Inoue H., Permutt M.A. Activation of serum response factor in the depolarization induction of Egr-1 transcription in pancreatic islet beta-cells. Journal of Biological Chemistry. 2000;275:25681–25689. doi: 10.1074/jbc.M003424200. [DOI] [PubMed] [Google Scholar]
- 93.Welsh M., Brunstedt J., Hellerstrom C. Effects of D-glucose, L-leucine, and 2-ketoisocaproate on insulin mRNA levels in mouse pancreatic islets. Diabetes. 1986;35:228–231. doi: 10.2337/diab.35.2.228. [DOI] [PubMed] [Google Scholar]
- 94.Welsh M., Nielsen D.A., MacKrell A.J., Steiner D.F. Control of insulin gene expression in pancreatic beta-cells and in an insulin-producing cell line, RIN-5F cells. II. Regulation of insulin mRNA stability. Journal of Biological Chemistry. 1985;260:13590–13594. [PubMed] [Google Scholar]
- 95.Dadi P.K., Vierra N.C., Ustione A., Piston D.W., Colbran R.J., Jacobson D.A. Inhibition of pancreatic beta-cell Ca2+/calmodulin-dependent protein kinase II reduces glucose-stimulated calcium influx and insulin secretion, impairing glucose tolerance. Journal of Biological Chemistry. 2014;289:12435–12445. doi: 10.1074/jbc.M114.562587. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.Shin S., Le Lay J., Everett L.J., Gupta R., Rafiq K., Kaestner K.H. CREB mediates the insulinotropic and anti-apoptotic effects of GLP-1 signaling in adult mouse beta-cells. Molecular Metabolism. 2014;3:803–812. doi: 10.1016/j.molmet.2014.08.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97.Ribar T.J., Epstein P.N., Overbeek P.A., Means A.R. Targeted overexpression of an inactive calmodulin that binds Ca2+ to the mouse pancreatic beta-cell results in impaired secretion and chronic hyperglycemia. Endocrinology. 1995;136:106–115. doi: 10.1210/endo.136.1.7828519. [DOI] [PubMed] [Google Scholar]
- 98.Blanchet E., Van de Velde S., Matsumura S., Hao E., LeLay J., Kaestner K. Feedback inhibition of CREB signaling promotes beta cell dysfunction in insulin resistance. Cell Reports. 2015;10:1149–1157. doi: 10.1016/j.celrep.2015.01.046. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99.Nielsen J.H., Mandrup-Poulsen T., Nerup J. Direct effects of cyclosporin A on human pancreatic beta-cells. Diabetes. 1986;35:1049–1052. doi: 10.2337/diab.35.9.1049. [DOI] [PubMed] [Google Scholar]
- 100.Johnson J.D., Ao Z., Ao P., Li H., Dai L.J., He Z. Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets. Cell Transplantation. 2009;18:833–845. doi: 10.3727/096368909X471198. [DOI] [PubMed] [Google Scholar]
- 101.Keller M.P., Paul P.K., Rabaglia M.E., Stapleton D.S., Schueler K.L., Broman A.T. The transcription factor Nfatc2 regulates beta-cell proliferation and genes associated with type 2 diabetes in mouse and human islets. PLoS Genetics. 2016;12 doi: 10.1371/journal.pgen.1006466. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102.Santos G.J., Ferreira S.M., Ortis F., Rezende L.F., Li C., Naji A. Metabolic memory of beta-cells controls insulin secretion and is mediated by CaMKII. Molecular Metabolism. 2014;3:484–489. doi: 10.1016/j.molmet.2014.03.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Krueger K.A., Ings E.I., Brun A.M., Landt M., Easom R.A. Site-specific phosphorylation of synapsin I by Ca2+/calmodulin-dependent protein kinase II in pancreatic betaTC3 cells: synapsin I is not associated with insulin secretory granules. Diabetes. 1999;48:499–506. doi: 10.2337/diabetes.48.3.499. [DOI] [PubMed] [Google Scholar]
- 104.Sweet I.R., Gilbert M. Contribution of calcium influx in mediating glucose-stimulated oxygen consumption in pancreatic islets. Diabetes. 2006;55:3509–3519. doi: 10.2337/db06-0400. [DOI] [PubMed] [Google Scholar]
- 105.Jung S.R., Reed B.J., Sweet I.R. A highly energetic process couples calcium influx through L-type calcium channels to insulin secretion in pancreatic beta-cells. American Journal of Physiology. Endocrinology and Metabolism. 2009;297:E717–E727. doi: 10.1152/ajpendo.00282.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106.De Marchi U., Thevenet J., Hermant A., Dioum E., Wiederkehr A. Calcium co-regulates oxidative metabolism and ATP synthase-dependent respiration in pancreatic beta cells. Journal of Biological Chemistry. 2014;289:9182–9194. doi: 10.1074/jbc.M113.513184. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107.Stamateris R.E., Sharma R.B., Kong Y., Ebrahimpour P., Panday D., Ranganath P. Glucose induces mouse beta-cell proliferation via IRS2, MTOR, and cyclin D2 but not the insulin receptor. Diabetes. 2016;65:981–995. doi: 10.2337/db15-0529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108.Alonso L.C., Yokoe T., Zhang P., Scott D.K., Kim S.K., O'Donnell C.P. Glucose infusion in mice: a new model to induce beta-cell replication. Diabetes. 2007;56:1792–1801. doi: 10.2337/db06-1513. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.Levitt H.E., Cyphert T.J., Pascoe J.L., Hollern D.A., Abraham N., Lundell R.J. Glucose stimulates human beta cell replication in vivo in islets transplanted into NOD-severe combined immunodeficiency (SCID) mice. Diabetologia. 2011;54:572–582. doi: 10.1007/s00125-010-1919-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 110.Porat S., Weinberg-Corem N., Tornovsky-Babaey S., Schyr-Ben-Haroush R., Hija A., Stolovich-Rain M. Control of pancreatic beta cell regeneration by glucose metabolism. Cell Metabolism. 2011;13:440–449. doi: 10.1016/j.cmet.2011.02.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111.Hija A., Salpeter S., Klochendler A., Grimsby J., Brandeis M., Glaser B. G0-G1 transition and the restriction point in pancreatic beta-cells in vivo. Diabetes. 2014;63:578–584. doi: 10.2337/db12-1035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112.Shen W., Taylor B., Jin Q., Nguyen-Tran V., Meeusen S., Zhang Y.Q. Inhibition of DYRK1A and GSK3B induces human beta-cell proliferation. Nature Communications. 2015;6:8372. doi: 10.1038/ncomms9372. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 113.Wang W., Walker J.R., Wang X., Tremblay M.S., Lee J.W., Wu X. Identification of small-molecule inducers of pancreatic beta-cell expansion. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:1427–1432. doi: 10.1073/pnas.0811848106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 114.Liu B., Barbosa-Sampaio H., Jones P.M., Persaud S.J., Muller D.S. The CaMK4/CREB/IRS-2 cascade stimulates proliferation and inhibits apoptosis of beta-cells. PLoS One. 2012;7 doi: 10.1371/journal.pone.0045711. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 115.Roche E., Buteau J., Aniento I., Reig J.A., Soria B., Prentki M. Palmitate and oleate induce the immediate-early response genes c-fos and nur-77 in the pancreatic beta-cell line INS-1. Diabetes. 1999;48:2007–2014. doi: 10.2337/diabetes.48.10.2007. [DOI] [PubMed] [Google Scholar]
- 116.Impey S., McCorkle S.R., Cha-Molstad H., Dwyer J.M., Yochum G.S., Boss J.M. Defining the CREB regulon: a genome-wide analysis of transcription factor regulatory regions. Cell. 2004;119:1041–1054. doi: 10.1016/j.cell.2004.10.032. [DOI] [PubMed] [Google Scholar]
- 117.Tessem J.S., Moss L.G., Chao L.C., Arlotto M., Lu D., Jensen M.V. Nkx6.1 regulates islet beta-cell proliferation via Nr4a1 and Nr4a3 nuclear receptors. Proceedings of the National Academy of Sciences of the United States of America. 2014;111:5242–5247. doi: 10.1073/pnas.1320953111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 118.Dai C., Hang Y., Shostak A., Poffenberger G., Hart N., Prasad N. Age-dependent human beta cell proliferation induced by glucagon-like peptide 1 and calcineurin signaling. Journal of Clinical Investigation. 2017;127:3835–3844. doi: 10.1172/JCI91761. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 119.Wang P., Alvarez-Perez J.C., Felsenfeld D.P., Liu H., Sivendran S., Bender A. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. Nature Medicine. 2015;21:383–388. doi: 10.1038/nm.3820. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 120.Dirice E., Walpita D., Vetere A., Meier B.C., Kahraman S., Hu J. Inhibition of DYRK1A stimulates human beta-cell proliferation. Diabetes. 2016;65:1660–1671. doi: 10.2337/db15-1127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 121.Demozay D., Tsunekawa S., Briaud I., Shah R., Rhodes C.J. Specific glucose-induced control of insulin receptor substrate-2 expression is mediated via Ca2+-dependent calcineurin/NFAT signaling in primary pancreatic islet beta-cells. Diabetes. 2011;60:2892–2902. doi: 10.2337/db11-0341. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 122.Soleimanpour S.A., Crutchlow M.F., Ferrari A.M., Raum J.C., Groff D.N., Rankin M.M. Calcineurin signaling regulates human islet beta-cell survival. Journal of Biological Chemistry. 2010;285:40050–40059. doi: 10.1074/jbc.M110.154955. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 123.Srinivasan S., Bernal-Mizrachi E., Ohsugi M., Permutt M.A. Glucose promotes pancreatic islet beta-cell survival through a PI 3-kinase/Akt-signaling pathway. American Journal of Physiology. Endocrinology and Metabolism. 2002;283:E784–E793. doi: 10.1152/ajpendo.00177.2002. [DOI] [PubMed] [Google Scholar]
- 124.Ricordi C., Zeng Y.J., Alejandro R., Tzakis A., Venkataramanan R., Fung J. In vivo effect of FK506 on human pancreatic islets. Transplantation. 1991;52:519–522. doi: 10.1097/00007890-199109000-00026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 125.Drachenberg C.B., Klassen D.K., Weir M.R., Wiland A., Fink J.C., Bartlett S.T. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation. 1999;68:396–402. doi: 10.1097/00007890-199908150-00012. [DOI] [PubMed] [Google Scholar]
- 126.Johnston O., Rose C.L., Webster A.C., Gill J.S. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. Journal of the American Society of Nephrology. 2008;19:1411–1418. doi: 10.1681/ASN.2007111202. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 127.Krentz A.J., Dousset B., Mayer D., McMaster P., Buckels J., Cramb R. Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients. Diabetes. 1993;42:1753–1759. doi: 10.2337/diab.42.12.1753. [DOI] [PubMed] [Google Scholar]
- 128.Costes S., Vandewalle B., Tourrel-Cuzin C., Broca C., Linck N., Bertrand G. Degradation of cAMP-responsive element-binding protein by the ubiquitin-proteasome pathway contributes to glucotoxicity in beta-cells and human pancreatic islets. Diabetes. 2009;58:1105–1115. doi: 10.2337/db08-0926. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129.Sabatini P.V., Krentz N.A., Zarrouki B., Westwell-Roper C.Y., Nian C., Uy R.A. Npas4 is a novel activity-regulated cytoprotective factor in pancreatic beta-cells. Diabetes. 2013;62:2808–2820. doi: 10.2337/db12-1527. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 130.Speckmann T., Sabatini P.V., Nian C., Smith R.G., Lynn F.C. Npas4 transcription factor expression is regulated by calcium signaling pathways and prevents tacrolimus-induced cytotoxicity in pancreatic beta cells. Journal of Biological Chemistry. 2016;291:2682–2695. doi: 10.1074/jbc.M115.704098. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 131.Oyadomari S., Takeda K., Takiguchi M., Gotoh T., Matsumoto M., Wada I. Nitric oxide-induced apoptosis in pancreatic beta cells is mediated by the endoplasmic reticulum stress pathway. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:10845–10850. doi: 10.1073/pnas.191207498. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 132.Gwiazda K.S., Yang T.L., Lin Y., Johnson J.D. Effects of palmitate on ER and cytosolic Ca2+ homeostasis in beta-cells. American Journal of Physiology. Endocrinology and Metabolism. 2009;296:E690–E701. doi: 10.1152/ajpendo.90525.2008. [DOI] [PubMed] [Google Scholar]
- 133.Hara T., Mahadevan J., Kanekura K., Hara M., Lu S., Urano F. Calcium efflux from the endoplasmic reticulum leads to beta-cell death. Endocrinology. 2014;155:758–768. doi: 10.1210/en.2013-1519. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 134.Moore C.E., Omikorede O., Gomez E., Willars G.B., Herbert T.P. PERK activation at low glucose concentration is mediated by SERCA pump inhibition and confers preemptive cytoprotection to pancreatic beta-cells. Molecular Endocrinology. 2011;25:315–326. doi: 10.1210/me.2010-0309. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 135.Rutter G.A., Hodson D.J., Chabosseau P., Haythorne E., Pullen T.J., Leclerc I. Local and regional control of calcium dynamics in the pancreatic islet. Diabetes, Obesity and Metabolism. 2017;19(Suppl 1):30–41. doi: 10.1111/dom.12990. [DOI] [PubMed] [Google Scholar]
- 136.Tarasov A.I., Semplici F., Ravier M.A., Bellomo E.A., Pullen T.J., Gilon P. The mitochondrial Ca2+ uniporter MCU is essential for glucose-induced ATP increases in pancreatic beta-cells. PLoS One. 2012;7 doi: 10.1371/journal.pone.0039722. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 137.Tarasov A.I., Semplici F., Li D., Rizzuto R., Ravier M.A., Gilon P. Frequency-dependent mitochondrial Ca(2+) accumulation regulates ATP synthesis in pancreatic beta cells. Pflügers Archiv. 2013;465:543–554. doi: 10.1007/s00424-012-1177-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 138.Bonnefond A., Froguel P. Rare and common genetic events in type 2 diabetes: what should biologists know? Cell Metabolism. 2015;21:357–368. doi: 10.1016/j.cmet.2014.12.020. [DOI] [PubMed] [Google Scholar]
- 139.Zeggini E., Scott L.J., Saxena R., Voight B.F., Marchini J.L., Hu T. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nature Genetics. 2008;40:638–645. doi: 10.1038/ng.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 140.Thurner M., van de Bunt M., Torres J.M., Mahajan A., Nylander V., Bennett A.J. Integration of human pancreatic islet genomic data refines regulatory mechanisms at type 2 diabetes susceptibility loci. Elife. 2018;7 doi: 10.7554/eLife.31977. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 141.Bonas-Guarch S., Guindo-Martinez M., Miguel-Escalada I., Grarup N., Sebastian D., Rodriguez-Fos E. Re-analysis of public genetic data reveals a rare X-chromosomal variant associated with type 2 diabetes. Nature Communications. 2018;9:321. doi: 10.1038/s41467-017-02380-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 142.Bernal-Mizrachi E., Cras-Meneur C., Ye B.R., Johnson J.D., Permutt M.A. Transgenic overexpression of active calcineurin in beta-cells results in decreased beta-cell mass and hyperglycemia. PLoS One. 2010;5 doi: 10.1371/journal.pone.0011969. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 143.Kato I., Oya T., Suzuki H., Takasawa K., Ichsan A.M., Nakada S. A novel model of insulin-dependent diabetes with renal and retinal lesions by transgenic expression of CaMKIIalpha (Thr286Asp) in pancreatic beta-cells. Diabetes or Metabolism Research and Reviews. 2008;24:486–497. doi: 10.1002/dmrr.864. [DOI] [PubMed] [Google Scholar]
- 144.Epstein P.N., Overbeek P.A., Means A.R. Calmodulin-induced early-onset diabetes in transgenic mice. Cell. 1989;58:1067–1073. doi: 10.1016/0092-8674(89)90505-9. [DOI] [PubMed] [Google Scholar]
- 145.Greenwood R.H., Mahler R.F., Hales C.N. Improvement in insulin secretion in diabetes after diazoxide. Lancet. 1976;1:444–447. doi: 10.1016/s0140-6736(76)91473-2. [DOI] [PubMed] [Google Scholar]
- 146.Guldstrand M., Grill V., Bjorklund A., Lins P.E., Adamson U. Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes. Diabetes & Metabolism. 2002;28:448–456. [PubMed] [Google Scholar]
- 147.Defronzo R.A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–795. doi: 10.2337/db09-9028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 148.Wang J., Takeuchi T., Tanaka S., Kubo S.K., Kayo T., Lu D. A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. Journal of Clinical Investigation. 1999;103:27–37. doi: 10.1172/JCI4431. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 149.Huang C.J., Lin C.Y., Haataja L., Gurlo T., Butler A.E., Rizza R.A. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes. 2007;56:2016–2027. doi: 10.2337/db07-0197. [DOI] [PubMed] [Google Scholar]
- 150.Sargsyan E., Ortsater H., Thorn K., Bergsten P. Diazoxide-induced beta-cell rest reduces endoplasmic reticulum stress in lipotoxic beta-cells. Journal of Endocrinology. 2008;199:41–50. doi: 10.1677/JOE-08-0251. [DOI] [PubMed] [Google Scholar]
- 151.Zhou Y., Sun P., Wang T., Chen K., Zhu W., Wang H. Inhibition of calcium influx reduces dysfunction and apoptosis in lipotoxic pancreatic beta-cells via regulation of endoplasmic reticulum stress. PLoS One. 2015;10 doi: 10.1371/journal.pone.0132411. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 152.Dahan T., Ziv O., Horwitz E., Zemmour H., Lavi J., Swisa A. Pancreatic beta-cells express the fetal islet hormone gastrin in rodent and human diabetes. Diabetes. 2017;66:426–436. doi: 10.2337/db16-0641. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 153.Szabat M., Page M.M., Panzhinskiy E., Skovso S., Mojibian M., Fernandez-Tajes J. Reduced insulin production relieves endoplasmic reticulum stress and induces beta cell proliferation. Cell Metabolism. 2016;23:179–193. doi: 10.1016/j.cmet.2015.10.016. [DOI] [PubMed] [Google Scholar]
- 154.Stancill J.S., Cartailler J.P., Clayton H.W., O'Connor J.T., Dickerson M.T., Dadi P.K. Chronic beta-cell depolarization impairs beta-cell identity by disrupting a network of Ca(2+)-regulated genes. Diabetes. 2017;66:2175–2187. doi: 10.2337/db16-1355. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 155.Dula S.B., Jecmenica M., Wu R., Jahanshahi P., Verrilli G.M., Carter J.D. Evidence that low-grade systemic inflammation can induce islet dysfunction as measured by impaired calcium handling. Cell Calcium. 2010;48:133–142. doi: 10.1016/j.ceca.2010.07.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 156.Ramadan J.W., Steiner S.R., O'Neill C.M., Nunemaker C.S. The central role of calcium in the effects of cytokines on beta-cell function: implications for type 1 and type 2 diabetes. Cell Calcium. 2011;50:481–490. doi: 10.1016/j.ceca.2011.08.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 157.Xu G., Chen J., Jing G., Shalev A. Preventing beta-cell loss and diabetes with calcium channel blockers. Diabetes. 2012;61:848–856. doi: 10.2337/db11-0955. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 158.Yu W., Niwa T., Miura Y., Horio F., Teradaira S., Ribar T.J. Calmodulin overexpression causes Ca(2+)-dependent apoptosis of pancreatic beta cells, which can be prevented by inhibition of nitric oxide synthase. Laboratory Investigation. 2002;82:1229–1239. doi: 10.1097/01.lab.0000027921.01548.c5. [DOI] [PubMed] [Google Scholar]
- 159.Do O.H., Low J.T., Gaisano H.Y., Thorn P. The secretory deficit in islets from db/db mice is mainly due to a loss of responding beta cells. Diabetologia. 2014;57:1400–1409. doi: 10.1007/s00125-014-3226-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 160.Rose T., Efendic S., Rupnik M. Ca2+-secretion coupling is impaired in diabetic Goto Kakizaki rats. The Journal of General Physiology. 2007;129:493–508. doi: 10.1085/jgp.200609604. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 161.Antonelli A., Ferrannini E. CD38 autoimmunity: recent advances and relevance to human diabetes. Journal of Endocrinological Investigation. 2004;27:695–707. doi: 10.1007/BF03347507. [DOI] [PubMed] [Google Scholar]


